CGRP, PACAP & Beyond: The Future of Migraine Relief
Key Questions
- What has been the clinical impact of CGRP inhibitors in migraine treatment so far?
- How many people with migraine respond to CGRP inhibitors, and what are the main challenges for non-responders?
- Should efficacy of CGRP inhibitors be measured only by reduction in attack frequency?
- Are there biomarkers that reliably predict response to CGRP inhibitors?
- Which new peptides —PACAP, adrenomedullin, and amylin — are being studied, and how could treatments targeting them differ from CGRP inhibitors?
- How are new drug targets identified and potential migraine treatments tested?
- How do the different pain fiber pathways — A-delta (targeted by CGRP inhibitors) and C-fibers (targeted by Botox) — influence treatment decisions?
- How should treatment decisions about combining therapies, like CGRP monoclonal antibodies and Botox, balance randomized trial evidence with real-world clinical experience?
- Which emerging migraine treatments are in advanced clinical trials?
- What can people with migraine do while awaiting the next major treatment breakthrough?
Messoud Ashina, MD, PhD, DMSc
Professor of Neurology | Centre Leader
Danish Headache Center | Center for Discoveries in Migraine
Messoud Ashina, MD, is a professor of neurology in the faculty of health and medical sciences, University of Copenhagen, Denmark. Professor Ashina received his doctor of medicine degree at the Azerbaijan Medical University. He completed his residency in neurology at the University of Copenhagen. Dr. Ashina received his PhD and DMSc degrees at the University of Copenhagen.
He is director of the Center for Discoveries in Migraine at the Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup.
Professor Ashina has been actively involved in headache research since 1995. His research interests include experimental migraine and cluster headache models, neuroimaging, novel antimigraine drug targets, the mechanism of migraine, and the action of antimigraine medications. He has authored over 600 papers, abstracts, and book chapters on the topic of headache, including migraine and cluster headache.
Professor Ashina serves as associate editor of two journals: Brain, and The Journal of Headache and Pain. He is also past president of the International Headache Society.
Interviews from Messoud Ashina, MD, PhD, DMSc
Beyond 50: Insights Into Migraine That Ages With Us
Migraine & Headache Research Frontiers
10 Steps to Migraine Management Your Doctor Should be Taking
Pre-purchase full access to the entire 2026 Summit, including:
- Every 2026 expert interview, fully unlocked
- Built for real life with migraine
- A trusted reference you can come back to for years
- And more!
Related Talks for: Day 8 (2026)
Why Isn’t There a Cure for Headache Disorders?
Tom Zeller Jr.
Small, Sustainable Lifestyle Changes To Help Minimize Migraine
Rebecca Erwin Wells, MD, MPH, FAHS, FAAN
Told You’re “Out of Options”? There’s Hope
Lauren R. Natbony, MD, FAHS
Migraine Canada is the only national, volunteer-based charity focused on supporting all Canadians impacted by migraine and other headache conditions.
We are transforming the lives of people affected by migraine and headache conditions through awareness campaigns, education and support programs, advocacy and research.
